arrow
A

Aisha Vadhariya

Eli Lilly
H指数:9
被引数:430

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment persistence of mirikizumab in a largely advanced treatment experienced cohort of adults with ulcerative colitis: a retrospective study using German prescription data

溃疡性结肠炎患者中mirikizumab的治疗持续性:一项基于德国处方数据的回顾性研究,研究对象为具有丰富先进治疗经验的人群

2026-01-010
PRE
Treatment sequencing patterns and healthcare resource utilization in patients with Crohn's disease initiating biologics: a 3-year retrospective claims-based analysis

克罗恩病患者启动生物制剂治疗的治疗顺序模式与医疗资源利用:一项基于3年回顾性索赔数据的分析

2025-11-010
PRE
Patient-Level Dynamics of Clinical Response to Mirikizumab and Its Impact on Quality of Life: Analysis From the Vivid-1 Trial in Crohn's Disease

克罗恩病患者对Mirikizumab临床反应的个体水平动态及其对生活质量的影响:来自Vivid-1试验的分析

2025-10-010
PRE
Mirikizumab Long-Term Impact on Bowel Urgency in Crohn's Disease and Its Association With Clinical and Other Efficacy Outcomes: Results From the VIVID-2 Open-Label Extension Study

Mirikizumab 对克罗恩病肠道急迫性的长期影响及其与临床及其他疗效结果的关联:VIVID-2 开放标签扩展研究的结果

2025-10-010
PRE
Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial

克罗恩病中的肠道急迫感:美利曲珠单抗在随机对照III期试验中的效果

2025-07-140
OAAI
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study

mirikizumab治疗对中度至重度活动性克罗恩病患者乏力的影响: 3期VIVID-1研究的结果

2025-07-010
OA